Eicosapentaenoic acid potentiates the therapeutic effects of adipose tissue-derived mesenchymal stromal cells on lung and distal organ injury in experimental sepsis

Stem Cell Research and Therapy

Volumn 10, Issue 1, 2019, Pages

  Silva, Johnatas D ^a   Lopes Pacheco, Miquéias ^a,c   De Castro, Ligia L ^a   Kitoko, Jamil Z ^a   Trivelin, Stefano A ^a   Amorim, Natália R ^a   Capelozzi, Vera L ^b   Morales, Marcelo M ^a,c   Gutfilen, Bianca ^a   De Souza, Sergio A L ^a   Weiss, Daniel J ^d   Diaz, Bruno L ^a   Rocco, Patricia R M ^a,c  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c National Institute for Science and Technology Translational Medicine   (Brazil)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Eicosapentaenoic acid; Inflammation; Macrophages; Mesenchymal stromal cells; Preconditioning; Sepsis

Indexed keywords

ICOSAPENTAENOIC ACID; INTERLEUKIN 10; INTERLEUKIN 1BETA; NUCLEAR PROTEIN; PROSTAGLANDIN E2; RESOLVIN D1; TECHNETIUM 99M; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; AUTACOID; CYTOKINE;

ACID SECRETION; ACUTE KIDNEY TUBULE NECROSIS; ADIPOSE TISSUE CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CELL; C57BL 6 MOUSE; CARDIAC MUSCLE CELL; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL VIABILITY; CELLULAR DISTRIBUTION; COHORT ANALYSIS; COLLAGEN FIBER; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL SEPSIS; FEMALE; HISTOLOGY; IN VITRO STUDY; KERATINOCYTE; KUPFFER CELL; LUNG EDEMA; LUNG INJURY; LUNG MECHANICS; LUNG PARENCHYMA; LYMPHOCYTE; MALE; MEGAKARYOCYTE; MESENCHYMAL STROMA CELL; MORPHOLOGICAL TRAIT; MOUSE; NEUTROPHIL COUNT; NONHUMAN; ORGAN INJURY; PRIORITY JOURNAL; PROTEIN EXPRESSION LEVEL; SPLEEN CELL; SURVIVAL RATE; THERAPY EFFECT; ADIPOSE TISSUE; ANIMAL; C57BL MOUSE; COMPLICATION; CYTOLOGY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; SEPSIS;

ADIPOSE TISSUE; ANIMALS; COMBINED MODALITY THERAPY; CYTOKINES; EICOSAPENTAENOIC ACID; INFLAMMATION MEDIATORS; LUNG INJURY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; SEPSIS;

EID: 85071427763     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-019-1365-z     Document Type: Article

References (44)

1. Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ. 2016;353:i1585.
2. Duggal A, Ganapathy A, Ratnapalan M, Adhikari NK. Pharmacological treatments for acute respiratory distress syndrome: systematic review. Minerva Anestesiol. 2015;81:567-88.
3. Antunes MA, Abreu SC, Cruz F, Teixeira AC, Lopes-Pacheco M, Bandeira E, et al. Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema. Respir Res. 2014;15:118.
4. Morrison TJ, Jackson MV, Cunningham EK, Kissenpgenning A, McAuley DF, O'Kane CM, Krasnodembskaya AD. Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicles mitochondrial transfer. Am J Respir Crit Care Med. 2017;196:1275-86.
5. Silva JD, Lopes-Pacheco M, Paz AHR, Cruz FF, Melo EB, de Oliveira M, et al. Mesenchymal stem cells from bone marrow, adipose tissue, and lung tissue differentially mitigate lung and distal organ damage in experimental acute respiratory distress syndrome. Crit Care Med. 2018;46:e132-40.
6. Abreu SC, Xisto DG, de Oliveira TB, Blanco NG, de Castro LL, Kitoko JZ, et al. Serum from asthmatic mice potentiates the therapeutic effects of mesenchymal stromal cells in experimental allergic asthma. Stem Cells Transl Med. 2019;8:301-12.
7. Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW, et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol. 2012;302:L1003-13.
8. Alcayaga-Miranda F, Cuenca J, Martin A, Contreras L, Figeuroa FE, Khoury M. Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis. Stem Cell Res Ther. 2015;6:199.
9. Chen HH, Lin KC, Wallace CG, Chen YT, Yang CC, Leu S, et al. Additional benefit of combined therapy with melatonin and apoptotic adipose-derived mesenchymal stem cell against sepsis-induced kidney injury. J Pineal Res. 2014;57:16-32.
10. Condor JM, Rodrigues CE, Sousa Moreira R, Canale D, Volpini RA, Shimizu MH, et al. Treatment with human Wharton's jelly-derived mesenchymal stem cells attenuated sepsis-induced kidney injury, liver, injury and endothelial dysfunction. Stem Cell Trans Med. 2016;5:1048-57.
11. Devaney J, Horie S, Masterson C, Elliman S, Barry F, O'Brien T, et al. Mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax. 2015;70:625-35.
12. Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15:39.
13. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3(1):24-32.
14. Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomized phased 2a safety trial. Lancet Respir Med. 2019;7:154-62.
15. Silva LHA, Antunes MA, Dos Santos CC, Weiss DJ, Cruz FF, Rocco PRM. Strategies to improve the therapeutic effects of mesenchymal stromal cells in respiratory diseases. Stem Cell Res Ther. 2018;9:45.
16. Lan YW, Choo KB, Chen CM, Hung TH, Chen YB, Hsieh CH, et al. Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Stem Cell Res Ther. 2015;6:97.
17. Abreu SC, Lopes-Pacheco M, da Silva AL, Xisto DG, de Oliveira TB, Kitoko JZ, et al. Eicosapentaenoic acid enhances the effects of mesenchymal stromal cell therapy in experimental allergic asthma. Front Immunol. 2018;9:1147.
18. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol. 2013;75:645-62.
19. Freitas HR, Isaac AR, Malcher-Lopes R, Diaz BL, Trevenzoli IH, De Melo Reis RA. Polyunsatured fatty acids and endocannabinoids in health and disease. Nutr Neurosci. 2018;21:695-714.
20. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI, Chaudry IH. Cecal ligation and puncture. Shock. 2005;24:(Suppl 1):52-7.
21. Zhang X, Goncalves R, Mosser DM. The isolation and characterization of murine macrophages. Curr Protoc Immunol. 2008;Chapter 14:Unit 14.1. https://doi.org/10.1002/0471142735.im1401s83.
22. Bates JH, Ludwig MS, Sly PD, Brown K, Martin JG, Fredberg JJ. Interrupter resistance elucidated by alveolar pressure measurement in open-chest normal dogs. J Appl Physiol (1985). 1988;65:408-14.
23. Hsia CC, Hyde DM, Ochs M, Weibel ER, et al. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med. 2010;181:394-418.
24. Silva JD, Paredes BD, Araújo IM, Lopes-Pacheco M, Oliveira MV, Suhett GD, et al. Effects of bone marrow-derived mononuclear cells from healthy or acute respiratory distress syndrome donors on recipient lung-injured mice. Crit Care Med. 2014;42:e510-24.
25. Lopes-Pacheco M, Ventura TG, de Oliveira HD, Monção-Ribeiro LC, Gutfilen B, dos Souza SA, et al. Infusion of bone marrow mononuclear cells reduces lung fibrosis but not inflammation in the late stage of murine silicosis. PLoS One. 2014;9:e109982.
26. Ruiz S, Vardon-Boues F, Merlet-Dupuy V, Conil JM, Buléon M, Fourcade I, et al. Sepsis modeling in mice: ligation length is a major severity factor in cecal ligation and puncture. Intensive Care Med Exp. 2016;4:22.
27. Mei SH, Haitsma JJ, dos Santos CC, Deng Y, Lai PF, Slutsky AS, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010;182:1047-57.
28. Nemeth K, Leelahavanichkyl A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprograming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15:42-9.
29. McIntyre LA, Moher D, Fergusson DA, Sullivan KJ, Mei SH, Lalu M, et al. Efficacy of mesenchymal stromal cell therapy for acute lung injury in preclinical animal models: a systemic review. PLoS One. 2016;11:e0147170.
30. Peng L, Jia Z, Yin X, Zhang X, Liu Y, Chen P, et al. Comparative analysis of mesenchymal stem cells from bone marrow, cartilage and adipose tissue. Stem Cells Dev. 2008;17:761-73.
31. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045.
32. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007;447:869-74.
33. Sun YP, Oh SF, Uddin J, Yang R, Gotlinger K, Campbell E, et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochamical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem. 2007;282:9323-34.
34. Araújo IM, Abreu SC, Maron-Gutierrez T, Cruz F, Fujisaki L, Carreira H Jr, et al. Bone marrow-derived mononuclear cell therapy in experimental pulmonary and extrapulmonary acute lung injury. Crit Care Med. 2010;38:1733-41.
35. Chang YS, Ahn SY, Jeon HB, Sung DK, Kim ES, Sung SI, et al. Critical role of vascular endothelial growth factor secreted by mesenchymal stem cells in hyperoxic lung injury. Am J Respir Cell Mol Biol. 2014;51:391-9.
36. Lee SH, Jang AS, Kim YE, Cha JY, Kim TH, Jung S, et al. Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis. Respir Res. 2010;11:16.
37. Yang Y, Hu S, Xu X, Li J, Liu A, Han J, Liu S, Liu L, Qiu H. The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in vivo. Mediat Inflamm. 2016; 2016:2347938.
38. Moore BB, Ballinger MN, White ES, Green ME, Herrygers AB, Wilke CA, et al. Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. J Immunol. 2005;174:5644-9.
39. Dackor RT, Cheng J, Voltz JW, Card JW, Ferguson CD, Garrett RC, et al. Prostaglandin E2 protects murine lung from bleomycin-induced pulmonary fibrosis and lung dysfunction. Am J Physiol Lung Cell Mol Physiol. 2011;301:L645-55.
40. Miyoshi H, VanDussen KL, Malvin NP, Ryu SH, Wang Y, Sonnek NM, et al. Prostaglandin E2 promotes intestinal repair through an adaptive cellular response of the epithelium. EMBO J. 2017;36:5-24.
41. Birrell MA, Maher SA, Dekkak B, Jones V, Wong S, Brook P, Belvisi MG. Anti-inflammatory of PGE2 in the lung: role of the EP4 receptor subtype. Thorax. 2015;70:740-7.
42. 2-dependent mechanism. Sci Rep. 2016;6:38308.
43. Mohammadzadeh M, Halabian R, Gharehbaghian A, Amirizadeh N, Jahaniam-Najafabadi A, Roushandeh AM, Roudkenar MH. Nrf-2 overexpression in mesenchymal stem cells reduced oxidative stress-induced apoptosis and cytotoxicity. Cell Stress Chaperones. 2012;27:553-65.
44. Lee FY, Chen KH, Wallace CG, Sung PH, Sheu JJ, Cheng SY, et al. Xenogeneic human umbilical cord-derived mesenchymal stem cells reduce mortality in rats with acute respiratory distress syndrome complicated by sepsis. Oncotarget. 2017;8:45626-42.